BioCentury | Oct 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies identified an inhibitor of the transmembrane domain of p75 NTR that could help treat melanoma. Screening of a compound library in a binding assay in bacteria expressing the...
BioCentury | Jun 26, 2018
Company News

No right-to-try for BrainStorm's ALS therapy

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) will not make its NurOwn therapy available under the U.S. right-to-try law, it announced Tuesday. NurOwn is in a Phase III trial to treat amyotrophic lateral sclerosis. It consists of...
BioCentury | Jun 7, 2018
Company News

BrainStorm considering right to try for ALS therapy

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) is considering offering NurOwn to treat amyotrophic lateral sclerosis under the recently enacted federal right-to-try law, BrainStorm President and CEO Chaim Lebovits told BioCentury. He also discussed the company’s plans...
BioCentury | Nov 3, 2017
Clinical News

BrainStorm starts Ph III of NurOwn to treat ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) began a Phase III trial of NurOwn (MSC-NTF cells) to treat amyotrophic lateral sclerosis (ALS). The double-blind, placebo-controlled, U.S. study will enroll about 200 patients. The primary endpoint is safety,...
BioCentury | Sep 15, 2017
Clinical News

Levicept begins Phase I of fusion protein for chronic pain

Levicept Ltd. (Sandwich, U.K.) began a Phase I trial to evaluate single ascending doses of its chronic pain candidate IV LEVI-04 (p75NTR-Fc) in healthy volunteers and in patients with pain due to osteoarthritis (OA) of...
BioCentury | Sep 14, 2017
Clinical News

Levicept begins Phase I of fusion protein for chronic pain

Levicept Ltd. (Sandwich, U.K.) began a Phase I trial of its chronic pain candidate IV LEVI-04 (p75NTR-Fc) in healthy volunteers and in patients with pain due to osteoarthritis (OA) of the knee. LEVI-04 is a...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

...and recovered normal function. In 2014, Liberman and colleagues published in eLife that overexpression of neurotrophin 3...
BioCentury | Feb 15, 2017
Distillery Techniques

Drug delivery

...recruitment to the locus - compared with the same Cas9-peptide conjugate plus a gRNA targeting neurotrophin 3 (NTF3)...
BioCentury | Sep 29, 2016
Distillery Therapeutics

Therapeutics: p75 neurotrophin receptor (p75 NTR); nerve growth factor (NGF)

Ophthalmic disease INDICATION: Diabetic retinopathy; ophthalmic Mouse studies suggest inhibiting p75 NTR or the precursor form of NGF could help treat diabetic retinopathy and other types of retinopathy. In a mouse model of diabetic retinopathy,...
BioCentury | Aug 15, 2016
Clinical News

NurOwn: Phase II data

Top-line data from a double-blind, placebo-controlled, U.S. Phase II trial in 48 patients with ALS showed that a single treatment of NurOwn administered by combined intramuscular and intrathecal injection was well tolerated with no treatment-related...
Items per page:
1 - 10 of 90